hydroxychloroquine has been researched along with Nausea in 12 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several case reports have highlighted symptomatic hypoglycemia as a serious but uncommon adverse effect of hydroxychloroquine (HCQ) in nondiabetic subjects." | 7.96 | Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. ( Dai, Y; Lin, G; Shi, D, 2020) |
| " The purpose of this study was to investigate whether combined treatment with the autophagy inhibitor: hydroxychloroquine (HCQ) and the autophagy inducer: sirolimus (rapamycin, Rapa) would reduce glucose utilization in sarcoma patients." | 5.20 | Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients. ( Chen, YK; Chi, KH; Chi, MS; Chung, CH; Huang, SC; Ko, HL; Lee, CY; Liao, KW; Yang, KL, 2015) |
| "Several case reports have highlighted symptomatic hypoglycemia as a serious but uncommon adverse effect of hydroxychloroquine (HCQ) in nondiabetic subjects." | 3.96 | Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. ( Dai, Y; Lin, G; Shi, D, 2020) |
| "Hydroxychloroquine is a valuable treatment for morphea because of its high response rate and low rate of adverse effects; however, prospective studies are needed to determine its true efficacy." | 1.51 | Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013. ( Blixt, EK; Drage, LA; El-Azhary, RA; Kumar, AB; Wetter, DA, 2019) |
| "To evaluate rates on the adverse side effect and discontinuation of second-line drugs frequently used in the treatment of rheumatoid arthritis (RA)." | 1.31 | [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs]. ( Jiang, L; Ni, L; Zhao, N, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Y | 1 |
| Lin, G | 1 |
| Shi, D | 1 |
| Kuraitis, D | 1 |
| Murina, A | 1 |
| Mattioli, M | 1 |
| Fustini, E | 1 |
| Gennarini, S | 1 |
| Akula, SM | 1 |
| McCubrey, JA | 1 |
| Zekarias, A | 1 |
| Watson, S | 1 |
| Vidlin, SH | 1 |
| Grundmark, B | 1 |
| Kishi, C | 1 |
| Motegi, SI | 1 |
| Yasuda, M | 1 |
| Ishikawa, O | 1 |
| Kumar, AB | 1 |
| Blixt, EK | 1 |
| Drage, LA | 1 |
| El-Azhary, RA | 1 |
| Wetter, DA | 1 |
| Chi, MS | 1 |
| Lee, CY | 1 |
| Huang, SC | 1 |
| Yang, KL | 1 |
| Ko, HL | 1 |
| Chen, YK | 1 |
| Chung, CH | 1 |
| Liao, KW | 1 |
| Chi, KH | 1 |
| Jiang, L | 1 |
| Zhao, N | 1 |
| Ni, L | 1 |
| Harris, ED | 1 |
| Prince, DS | 1 |
| Hardin, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma[NCT01842594] | Phase 2 | 13 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to Most patients completed only the primary objective (PET) and not went throught the secondary outcome (efficacy phase) of 8wks period.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A baseline whole-body [18F]-fluorodeoxyglucose(FDG) PET was performed before therapy initiation. Patients received 1 mg of Rapa and 200 mg of HCQ twice a day before a meal for 2 weeks. A second [18F]-FDG PET was performed after treatment completion. SUVs were calculated for all lesions. Regions of interest (ROI) were contoured to represent tumors (>2 cm) and organs (lungs, spleen, and liver) on all transaxial and coronal slices. ROIs were normalized for injection dose and body weight, and the maximum voxel value was recorded for each region or organ. The highest SUV measured with increased uptake was considered the SUVmax. Correlative diagnostic CT examinations were used for accurate localization of the lesions. The most intense uptake at baseline was identified as the index lesion and evaluated for treatment response. (NCT01842594)
Timeframe: 2 Weeks
| Intervention | percentage of the SUVmax Change (Mean) |
|---|---|
| Sirolimus and Hydroxychloroquine | -19.6 |
Number of Participants with Adverse Events. Toxicities parameters are according to the Nation Cancer Institute Common Terminology Criteria for Adverse Event, version 3.0. (NCT01842594)
Timeframe: 2 Weeks
| Intervention | participants (Number) |
|---|---|
| Sirolimus and Hydroxychloroquine | 3 |
1 review available for hydroxychloroquine and Nausea
| Article | Year |
|---|---|
Where are we with understanding of COVID-19?
Topics: Antiviral Agents; Ataxia; Betacoronavirus; Communicable Disease Control; Coronavirus Infections; COV | 2020 |
1 trial available for hydroxychloroquine and Nausea
| Article | Year |
|---|---|
Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophag | 2015 |
10 other studies available for hydroxychloroquine and Nausea
| Article | Year |
|---|---|
Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus.
Topics: Adult; Antirheumatic Agents; Blood Glucose; Connective Tissue Diseases; Dizziness; Fatigue; Female; | 2020 |
Facts, not Fear: Safety of Hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Agranulocytosis; Anemia, Aplastic; Antirheumatic Agents; | 2020 |
Heart transplant recipient patient with COVID-19 treated with tocilizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Cardiomyopathy, Dilated; C | 2020 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agent | 2020 |
Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Diarrhea; Drug Eruptions; Female; Humans; Hydroxychlo | 2018 |
Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013.
Topics: Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Child; Deglutition Disorders; Drug Eva | 2019 |
[Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Topics: Adult; Anorexia; Antirheumatic Agents; Arthritis, Rheumatoid; Exanthema; Female; Gastrointestinal Di | 2002 |
Electronic mail. A physician extender?
Topics: Adult; Computer Communication Networks; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Lupus | 1997 |
Drugs for rheumatoid arthritis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; An | 2000 |
Hydroxychloroquine-induced vertigo.
Topics: Administration, Oral; Arthritis, Rheumatoid; Female; Headache; Humans; Hydroxychloroquine; Middle Ag | 1975 |